Turbo Cancer Fears: Shocking New Data Demands Urgent Answers

🎧 ▶️ Press play below to listen.

Introduction

Since the rollout of COVID-19 vaccines, I have personally known several people who developed cancers that advanced with unusual speed. Some had been in remission for years, only to see a sudden recurrence that progressed from diagnosis to death within months. Others, previously healthy, faced new and unexpectedly aggressive cancers. If you’ve heard similar stories—or experienced them in your own family—you are not alone.

These cases have led many to use the term “turbo cancers” to describe this apparent acceleration. While such accounts are powerful, they are also anecdotal. What has been missing is a way to measure this concern objectively.

That is where this new study comes in. Conducted over 30 months in an Italian province and including nearly 300,000 people, it provides a rare population-level view of cancer hospitalizations after vaccination. By examining specific cancer sites and comparing vaccinated and unvaccinated groups, the study enables us to determine whether the phenomenon people describe has a detectable signal in the data.

Quick Summary

This 30-month cohort study followed nearly 300,000 residents of an Italian province to investigate the relationship between COVID-19 vaccination and all-cause mortality and cancer hospitalizations. The results showed that vaccinated individuals had lower overall mortality, but the picture for cancer was more complex.

• All-cancer hospitalizations were slightly higher among the vaccinated compared to the unvaccinated (HR 1.23 for ≥1 dose; HR 1.09 for ≥3 doses).
• By organ type, increased risks appeared for colon-rectum, breast, and bladder cancers, while other sites like lung, ovary, thyroid, and prostate showed no clear link or even reduced risks under certain conditions.
• The associations varied by sex (bladder signal only in men), by prior SARS-CoV-2 infection (no excess risk in those previously infected), and by the time lag used to count cancer events (signals disappeared or reversed at a 365-day lag).

Healthy Vaccinee Bias

Notably, the study highlights the role of healthy vaccinee bias, where vaccinated individuals are generally more health-conscious and more engaged with medical care, which likely explains the lower overall mortality rates.

At the same time, greater medical contact among vaccinees may have led to earlier detection and more hospitalizations for cancer, which could inflate the apparent cancer risk.

Bottom line: The study suggests intriguing signals for specific cancer sites, but these findings are strongly shaped by bias and methodology. More research with detailed pathology data and lifestyle factors is needed before drawing firm conclusions.

Study Design at a Glance

Population & Data Sources
The study followed nearly 300,000 residents aged 11 and older in a single Italian province over 30 months. Researchers linked together official health records that included vaccination registries, COVID-19 swab results, hospital admissions, and demographic information. This comprehensive approach made it possible to track vaccination status, infection history, and cancer outcomes in the entire population.

Outcomes Measured
The main outcome was the first hospital admission for cancer during the study period. To keep the results clear, skin cancers were excluded. Site-specific cancers were also analyzed, including:

• Colon and rectum
• Lung
• Breast
• Uterine body
• Ovary
• Prostate
• Bladder
• Thyroid
• Hematologic cancers (blood-related, like leukemia and lymphoma)

These were classified using international medical coding standards (ICD-9).

Comparisons & Timing
The study compared cancer hospitalization rates between:

• Unvaccinated individuals
• Those who had received at least one dose of a COVID-19 vaccine
• Those who had received three or more doses

To avoid counting cancers that might have already been developing before vaccination, the researchers applied a “lag period” between vaccination and outcome measurement.

• The primary lag was 180 days (6 months).
• Sensitivity analyses also tested 90 days and 365 days to see how results changed depending on the time window.

What Happened Across the Entire Population

All-Cause Mortality
People who received the COVID-19 vaccine had a much lower risk of dying from any cause compared to those who remained unvaccinated. This benefit was strong and consistent throughout the study period.

The researchers note, however, that this difference is influenced by the “healthy vaccinee bias”—meaning that people who choose to get vaccinated are often healthier and more engaged with the health system in the first place.

All-Cancer Hospitalizations (Any Site)
When looking at hospitalizations for any type of cancer, the picture was more complicated:

• At least one dose of vaccine: Hazard Ratio (HR) 1.23 (95% CI 1.11–1.37).
  • This means vaccinated individuals had about a 23% higher rate of being hospitalized for cancer compared to those who were unvaccinated.
• Three or more doses of vaccine: Hazard Ratio (HR) 1.09 (95% CI 1.02–1.16).
  • This translates to roughly a 9% higher hospitalization rate for cancer compared to the unvaccinated group.

In other words, across the entire cohort, vaccinated people were hospitalized for cancer somewhat more often than unvaccinated people. The increase was modest but statistically significant, especially after at least one dose.

Breaking It Down by Cancer Type

When the researchers looked at specific cancer sites, a few stood out with higher hospitalization rates among the vaccinated. Here are the main findings using the 180-day lag (the primary analysis window):

• Colon and Rectum Cancer
  • ≥1 dose: HR 1.35 → about 35% higher rate
  • ≥3 doses: HR 1.14 → about 14% higher rate (not statistically significant)
• Lung Cancer
  • ≥1 dose: HR 0.90 → about 10% lower rate
  • ≥3 doses: HR 0.93 → about 7% lower rate
  • Neither finding was statistically significant.
• Breast Cancer
  • ≥1 dose: HR 1.54 → about 54% higher rate
  • ≥3 doses: HR 1.36 → about 36% higher rate
  • Both findings were statistically significant.
• Uterine (Body) Cancer
  • ≥1 dose: HR 1.77 → about 77% higher rate (not significant due to wide confidence interval)
  • ≥3 doses: HR 1.20 → about 20% higher rate (not significant)
• Ovarian Cancer
  • ≥1 dose: HR 1.71 → about 71% higher rate (not significant)
  • ≥3 doses: HR 1.86 → about 86% higher rate (not statistically significant)
• Prostate Cancer
  • ≥1 dose: HR 1.01 → essentially no difference
  • ≥3 doses: HR 0.97 → about 3% lower rate (not significant)
• Bladder Cancer
  • ≥1 dose: HR 1.62 → about 62% higher rate
  • ≥3 doses: HR 1.43 → about 43% higher rate
  • Both findings were statistically significant.
• Thyroid Cancer
  • ≥1 dose: HR 1.58 → about 58% higher rate (not significant)
  • ≥3 doses: HR 0.97 → about 3% lower rate (not significant)
• Hematologic Cancers (blood cancers like leukemia and lymphoma)
  • ≥1 dose: HR 1.31 → about 31% higher rate (not significant)
  • ≥3 doses: HR 1.07 → about 7% higher rate (not significant)

---

Summary:

• The strongest and most consistent signals for higher hospitalization rates were seen in breast cancer and bladder cancer, with colon-rectum cancer also showing a modest increase.
• Other cancers either showed no clear link, wide uncertainty, or signals that disappeared after three doses.

👉 Importantly, the bladder cancer signal was seen only in men when the data were split by sex.

Looking Deeper: Stratified Analyses

The researchers didn’t stop at the overall numbers. They also looked at whether the cancer hospitalization risks changed depending on sex, prior COVID-19 infection, and the time gap after vaccination. Here’s what they found:

By Sex

• The increased risk for bladder cancer was found only in men.
• In women, this signal disappeared, suggesting the effect might be sex-specific or due to other differences not measured.

By Prior SARS-CoV-2 Infection

• Among individuals with no documented prior COVID-19 infection, vaccination was associated with a noticeable increase in cancer hospitalizations.
  • With ≥1 dose: HR 1.31 → about a 31% higher rate
  • With ≥3 doses: HR 1.11 → about an 11% higher rate
• Among people who had been infected at least 6 months earlier, these increases were not seen. In fact, the association sometimes went in the opposite direction, with a slight trend toward lower hospitalization rates.

By Time Lag (Window of Analysis)

• 90-day lag: Results were very similar to the primary 180-day analysis.
• 365-day lag: Things looked quite different:
  • For “any cancer,” those with ≥1 dose no longer had a significant increase.
  • For those with ≥3 doses, the risk actually shifted to a lower rate of cancer hospitalizations (HR 0.90 → about a 10% lower rate).
  • At this longer window, prostate and lung cancers even showed a protective signal with three or more doses.

---

This stratified look shows that the apparent increase in cancer risk after vaccination is not uniform. It varies by sex, by whether someone had a prior COVID-19 infection, and by how long after vaccination the researchers looked.

How to Interpret These Findings

When we see signals like these, it’s natural to ask: what do they really mean? The study itself points to several factors that help explain the results—and it’s essential to consider them carefully before jumping to conclusions.

1. The “Healthy Vaccinee Bias”

In medical research, this term typically refers to the fact that individuals who receive vaccinations tend to be healthier overall.

They often take better care of themselves, follow medical advice, and seek preventive care. This could partly explain why the vaccinated group in this study had a much lower risk of dying from any cause.

2. Another Side of Health-Consciousness

But the COVID-19 vaccine is not like a long-established flu shot—it’s a new technology without decades of long-term data. For many people, choosing not to take it was not a sign of neglecting their health.

Instead, it reflected a different kind of health awareness and caution: avoiding what they saw as a gamble with an untested intervention, and preferring to protect themselves through lifestyle and natural immunity. In this light, the unvaccinated group may also include people who are highly health-conscious but cautious in a different way.

3. More Health-Care Contact Means More Cancer Detection

Vaccinated individuals generally had more health-care contact, which could lead to earlier detection and more hospitalizations for cancer. Unvaccinated individuals, by contrast, may have had fewer encounters, which could mean under-detection of cancers.

But we must also remember the pandemic context. In 2021, during the early vaccine rollout, many people—vaccinated and unvaccinated—were still hesitant to visit doctors or hospitals for routine care. Fear of exposure to COVID-19 kept cancer screening and diagnostic visits down across the board. This likely contributed to fewer cancers being detected during that first year, regardless of vaccination status.

4. Timing, Pandemic Conditions, and Methodology Still Shape the Signal

When the researchers applied different “lag windows” (90, 180, 365 days), the results shifted. At 180 days, some cancers (colon, breast, bladder) looked higher in the vaccinated group. But at 365 days, these signals faded or even reversed.

Part of this change may reflect the return to regular medical care after the worst of the pandemic. As people began resuming checkups in 2022–2023, more cancers were diagnosed—especially in those with greater contact with the health system. This timing effect is layered on top of the methodological issues and shows just how complex it is to separate real biological effects from changes in health-care behavior during and after the pandemic.

---

In short:
The findings do show some signals that look concerning, but they are deeply influenced by bias, health-care contact, and timing. That means we can’t simply say the vaccines “cause” these cancers. Instead, the study highlights the need for more detailed research—linking vaccination status with confirmed cancer diagnoses, pathology records, and lifestyle factors—to truly understand what is happening.

Strengths, Limits, and What’s Next

Strengths of the Study

• Large population coverage: Nearly 300,000 people were included, representing an entire Italian province.
• Comprehensive data sources: Researchers linked vaccination registries, swab results, hospital admissions, and demographic data, reducing gaps in the record.
• Long follow-up: The study spanned 30 months, allowing patterns to be seen across different phases of the pandemic and vaccination campaigns.
• Multiple time windows tested: By analyzing 90-, 180-, and 365-day lags, the study showed how results depend on the chosen timeframe.

Limits and Caveats

• Healthy vaccinee bias: Traditionally, this means that people who get vaccinated are often healthier and more engaged with medical care, which lowers their overall risk of death. But in this case, the opposite may also apply—some unvaccinated individuals avoided the vaccine out of caution for their health, not neglect. This complicates the interpretation.
• Detection bias: Vaccinated individuals, with more regular contact with the health-care system, may have had cancers detected sooner. That can make hospitalization rates look higher in this group, even if the true incidence was not.
• Pandemic conditions: In 2021—the first year of vaccine rollout—many people (vaccinated or not) avoided clinics and hospitals due to fear of COVID-19. This likely reduced cancer detection across the board. As restrictions eased and people returned to care in 2022–2023, more cancers were diagnosed, influencing the apparent trends.
• Residual confounding: Lifestyle factors like smoking, diet, exercise, and family history of cancer were not available in the dataset. These could explain part of the observed differences.
• Outcome measure: The study used hospital admission for cancer as a proxy for cancer incidence. This excludes undiagnosed cancers or those treated outside of hospitals.

What’s Next

The study highlights signals that deserve closer attention, but it does not prove causation. Future research should:

• Link vaccination records to pathology-confirmed cancer diagnoses.
• Adjust for lifestyle factors (smoking, alcohol use, diet, exercise).
• Examine different cancer stages at diagnosis (were cancers more advanced, or just detected earlier?).
• Explore whether timing of vaccination relative to infection influences cancer risk.

---

Takeaway: This study offers an important first look at cancer risks in a vaccinated vs. unvaccinated population. While some cancers showed higher hospitalization rates, the findings are strongly influenced by bias, detection effects, and pandemic conditions. More detailed research is needed before firm conclusions can be drawn.

Practical Takeaways for Readers

This study raises important questions, but here’s what you can take home right now:

• Overall survival rates appeared to be better in the vaccinated group. Vaccinated people in this Italian province had lower all-cause mortality during the 30-month study. Some of this may be due to the vaccine, but some is also explained by differences in health behaviors and medical care access.
• Certain cancers showed higher hospitalization rates. Colon, breast, and bladder cancers were more often seen in vaccinated individuals, especially within 180 days. But these signals weakened or even reversed when longer time windows (365 days) were considered.
• Context matters. The early vaccine rollout took place in 2021, when many avoided doctors due to fear of COVID-19. This reduced cancer detection across the board. Later, as people returned to normal care, more cancers were found. This complicates interpretation.
• Bias and detection play a big role. Vaccinated people tend to see doctors more often, which means cancers may be caught and treated earlier. Unvaccinated people may delay care, leading to fewer hospitalizations recorded but not necessarily fewer cancers.
• This is not the final word. The study reveals signals worth investigating, although there is an associated higher risk of cancer with the COVID-19 vaccines. More detailed studies are needed—ones that track stage at detection, time from diagnosis to death, and include lifestyle factors like smoking and diet.

---

For readers:
If you or someone you know has noticed a faster progression of cancers in recent years, this study shows that you are not alone in your concerns. It doesn’t provide all the answers, but it does offer measurable data that researchers can build upon.

For the vaccinated, especially:
This article should not make you despondent or fearful. Instead, let it be a reminder of the power you still have over your health.

Regardless of vaccination status, proven strategies like healthy eating, regular exercise, maintaining a healthy weight, and avoiding smoking and excess alcohol can dramatically lower your lifetime cancer risk.

These behaviors have far more consistent evidence behind them than any single study, and they remain the foundation for preventing cancer and living longer, healthier lives.

Don’t Get Sick!

💡 Support This Work

Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.

🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!

Follow me on Facebook, Gab, Twitter (formerly known as X), and Telegram.

Related:

1. Turbo Cancers after the COVID shots
2. New and Alarming Autopsy Findings after the COVID shots
3. The Hidden Connection Between Hyperinsulinemia, Obesity, Inflammation, and Cancer
4. The Shocking Truth About Spike Proteins, Sugar And Inflammation
5. Spike Proteins, Blood Sugar at Inflammation: Alamin Ang Koneksyon
6. Benzimidazoles
7. Mebendazole: Repurposing Benzimidazoles As A Powerful New Weapon Against Cancer
8. Fenbendazole Warning: Lethal Liver Toxicity With Acetaminophen
9. SJS/TEN: Hidden Dangers Of Metronidazole & Mebendazole Combined
10. Mebendazole: A New Hope for Adrenocortical Cancer
11. Mebendazole Saves Man From Deadly Colon Cancer When Chemo Fails
12. When Science Meets Courage: One Man’s Path To Remission
13. Fighting Colon Cancer With Albendazole: A Potent Breakthrough You Need To Know
14. Mebendazole: A Bold Breakthrough In Brain Metastasis Battle
15. Breakthrough Treatment: How Mebendazole Boosts Radiation Therapy For TNBC
16. Outsmarting Cancer: How Mebendazole Offers Hope For Brain Tumors
17. Mebendazole And Cisplatin: A Hopeful Combination For Ovarian Cancer
18. New Lifesaver: How Benzimidazole Targets Drug-Resistant Metastatic Prostate Cancer
19. Mebendazole’s Power: A New Weapon Against Aggressive Breast Cancer

References:

• Acuti Martellucci, Cecilia, et al. “COVID-19 Vaccination, All-Cause Mortality, and Hospitalization for Cancer: 30-Month Cohort Study in an Italian Province.” EXCLI Journal, vol. 24, 2025, pp. 690–707. **doi:**10.17179/excli2025-8400. https://dx.doi.org/10.17179/excli2025-8400.

© 2018 – 2025 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment

As an Amazon Associate, I earn from qualifying purchases